Two Cases of Viral Re-suppression After M184V + R263K Selection on Dolutegravir/Lamivudine Without Treatment Modification.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 38193816.
- Also identified by DOI 10.1093/cid/ciae006.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Dolutegravir/lamivudine (DTG/3TC) has a high genetic barrier against the development of human immunodeficiency virus drug resistance. We report 2 cases of R263K + M184V mutations during DTG/3TC failure followed by viral suppression after adherence intervention without treatment change that we attribute to residual drug activity, reduced viral fitness, and robust immune competence.
Medical subject headings
- Anti-HIV Agents
- Drug Resistance, Viral
- Heterocyclic Compounds, 3-Ring
- HIV Infections
- Lamivudine
- Oxazines
- Piperazines
- Pyridones